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Abstract 
Gene therapy holds its promises to silence dysfunctional genes on either 
transcriptional or translational level or by replacement with functional genes. Not long 
ago it has revolutionized modern medicine and since then thousand clinical trials 
have been authorized worldwide.  
 To put the medical profit of gene therapy and DNA vaccination into practice, 
methods to produce highly pure plasmid DNA (pDNA) free from bacterial 
chromosomal DNA, RNA, proteins and endotoxins have to be developed. Since it is 
known that plasmid copy number (PCN) and plasmid stability are affecting the 
success of gene therapy to a large extent, the rational design of an optimized vector 
is an ultimate ambition. To prevent excessive plasmid replication, posing metabolic 
burden resulting in growth inhibition right up to cell death to the workhorse 
Escherichia coli (E. coli), regulation of PCN is to be considered in the rational design 
of any vector as well.  
In this work the main goal was to elaborate a system that regulates plasmid 
replication of ColE1-type plasmids in Escherichia Coli (E. coli) by overexpressing 
tRNAAlaU and rssB encoding genes. In the first approach the wt and mutated tRNAAlaU 
gene, whose expression was controlled by the T7 promoter, was inserted into the E. 
coli chromosome. In shake flask experiments overexpression of the tRNAAlaU gene 
was induced by addition of IPTG and subsequently its effect on three different ColE1-
type plasmids has been tested. In the second approach, overexpression of rssB, 
whose expression was also controlled by the T7 promoter, should result in enhanced 
plasmid concentration after IPTG induction whereas the biological mechanism 
remains unclear. In shake flask experiments, rssB overexpression was also induced 
by adding IPTG. 
 All in all, the experimentally gained data have demonstrated clearly that 
overexpression of rssB and tRNAAlaU encoding genes resulted in enhanced plasmid 
concentration of ColE1-type plasmids. 
Zusammenfassung 
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Zusammenfassung 
Die Gentherapie erscheint viel versprechend, fehlerhafte Gene auf transkriptioneller 
oder translationeller Ebene stillzulegen oder diese durch Rekombination mit 
funktionellen Genen zu korrigieren. Vor nicht allzu langer Zeit revolutionierte die 
Gentherapie die moderne Medizin und mehr als tausend vorgeschlagene oder 
laufende klinische Versuche wurden weltweit genehmigt. 
 Um das Potential der medizinischen Gentherapie und DNA-Impfung in die 
Praxis umzusetzen, muss die Herstellung hochreiner Plasmid-DNA (pDNA) 
sichergestellt werden, die frei von jedweder bakteriell chromosomaler DNA, RNA, 
Proteine und Endotoxine sein muss. Es ist bekannt, dass die Plasmidkopienzahl und 
Plasmid-Stabilität wesentliche Determinanten sind, die die Gendosis in der Wirtszelle 
beeinflussen. Daher ist das rationale Design eines pDNA Vektors ein großes Ziel im 
Rahmen der Gentherapie. Weiters ist bekannt, dass die Regulierung der PCN 
entscheidend ist, um eine metabolische Belastung der Wirtszelle zu verhindern, da 
sich eine übermäßige Plasmidreplikation wachstumshemmend auswirkt bis hin zum 
Zelltod führen kann. 
 
In dieser Arbeit sollte die Konzentration von Plasmiden des ColE1-Typs durch 
Überexpression des Gens rssB sowie tRNAAlaU in Escherichia Coli (E. coli) reguliert 
werden, die sich in der Literatur als erfolgreich erwiesen haben. 
 Im ersten Ansatz wurde das für die tRNAAlaU codierende Gen, das unter die 
Kontrolle des T7 Promoters gebracht wurde, in das E. coli Genom inseriert. In 
Schüttelkolbenexperimenten wurde die Überexpression des tRNAAlaU-Gens durch 
Zugabe von IPTG induziert und anschließend wurde dessen Auswirkung auf drei 
verschiedene Plasmide des ColE1-Typs getestet. 
 In einem zweiten Ansatz sollte die Überexpression des Gens rssB, das 
ebenso unter der Kontrolle des T7 Promotors stand, zu einer Erhöhung der 
Plasmidkonzentration nach IPTG-Zugabe führen, wobei der biologische 
Mechanismus bisher noch nicht vollständig geklärt ist. In 
Schüttelkolbenexperimenten wurde eine rssB-Überexpression durch Zugabe von 
IPTG induziert. 
Zusammenfassung 
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 Insgesamt konnte in dieser Arbeit gezeigt werden, dass eine Überexpression 
von rssB und tRNAAlaU zu einer sichtbaren Erhöhung der Plasmidkonzentration des 
ColE1-Typs geführt hat. 
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1 Introduction 
 
1.1 Bacterial Plasmids 
According to a present definition plasmids are no life form similar to viruses. 
Plasmids can be accounted for up to 50 % of bacterial DNA and they vary in their 
size: usually plasmids are small (up to 100 kb) but sometimes a precise distinction 
between plasmid and bacterial chromosome is hardly possible (e.g. Vibrio cholerae 
and Rhizobium meliloti). 
 Plasmids are extrachromosomal, circular and double-stranded (ds) DNA 
molecules. These so-called episomes are represented by a specific copy number 
within a convenient host as well as by its autonomous and self-controlled replication 
and have been observed in Archaea, Bacteria and Eukarya. Many plasmids contain 
adequate features making them suitable for a wide host range. Furthermore, 
plasmid-encoded genes are not essential but grant various advantages for the host 
such as antibiotic resistance, degradation/conversion of specific substances, 
pathogenicity and production of virulence factors (12). Plasmids can bring along 
genes by mechanisms like transposition or recombination contributing to genetic 
variety in bacterial population and new gene functions. Some plasmids can even 
break down genetic barriers of different species (26). So, plasmids can be regarded 
as a reservoir of extrachromosomal DNA which can be interchanged between 
bacterial populations but despite of various profits, plasmids are still a metabolic 
burden for the host. 
 
1.1.1 Replication of ColE1 plasmids 
In molecular biology derivatives of the ColE1-type plasmids pBR322, originated from 
the natural isolate pMB1, are frequently used tools for cloning purposes in E. coli 
(Balbas et al., 2004). According to Cesareni et al., the interaction between Repressor 
of primer (Rop) and RNAI and/or RNAII is determining the replication of ColE1-type 
plasmids (17). At least since the turn of the millennium, RNA has highlighted its 
biologically significance and various regulatory roles in different cellular processes 
including transcription, translation, RNA processing, and regulation of DNA 
1 Introduction 
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replication. Presumptively, plasmid copy number and incompatibility are depending 
on RNAI/RNAII interactions.  
 According to Eguchi et al., replication of ColE1-type replicons is a complex 
regulated process which starts 555 bp upstream of the ORI with the expression of 
plasmid-encoded RNAII species. RNAII persists in cis and form a stable duplex with 
its template DNA only when RNAII fold into a unique tertiary structure. In the next 
step, a free 3’-OH end of the RNA is generated by RNase H-mediated cleavage of 
the DNA –RNA hybrid leading to attachment and leading strand synthesis catalyzed 
by DNA polymerase I (DNAPI) (30).  
 Negative regulators of plasmid replication are RNAI and Rop/Rom. The 
plasmid-encoded RNAI is a 108-nt ColE1-encoded antisense RNA that is, in contrast 
to RNAII, active in trans. RNAI is exactly complementary to the 5’ part of RNAII and 
by hybridization to it (known as “kissing structure”) it prevents the formation of the 
RNAII-DNA hybrid (fig.1) (18). Subsequently, after RNAI hybridized with RNAII it will 
lead to conformational changes in the 5’-end of RNAII and end until the 3’-end of 
RNAII is reached. As a consequence, RNAII can not act as a primer (25) 
 The fast and reversible hybridization between these two RNA species has 
been studied for a long time but if the formation of the kissing complex alone can 
prevent primer formation or if a complete hybridization between the two RNA species 
is sufficient is not clear until now.  
According to Want et al., RNAI decay or cleavage itself is regulated by four 
factors: (1) RNaseE impairs endonucleolytic or exonucleolytic activity leading to 
RNAI decay; (2) polynucleotide phosphorylase act as an exonuclease involved in 
RNAI decay; (3) RNaseIII participated in RNAI degradation; and (4) poly(A) 
polymerase I is regulating ColE1-like PCN and RNAI degradation (8). 
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Fig.1: Binding of RNAI to RNAII is a multi-step process involving interaction at their loops. The 
hybridization process is initiated at the 5’-end of RNAI and comes to a standstill when both, RNAI and 
RNAII are completely hybridized (30). 
 
Expression of RNAI and RNAII is controlled by a constitutive promoter so that 
their intracellular concentration correlates always with the plasmid concentration. 
However, up to now experiments could not make clear the absolute rates of 
RNAI/RNAII. Lin-Chao et al. have measured that RNAI and RNAII molecules are 
expressed in a ratio of 3 to 1 whereas Polaczek et al. suggested that synthesis occur 
in a ratio of about 5.5 to 1 (41).  
 The Rop protein is also a negative regulator involved in PCN control. As 
shown in fig.2, Rop is a small dimeric protein, whose monomers show two tightly 
packed α-helices connected by a sharp bend (Banner et al., 1987). Helmer-Citterich 
et al. suggested that the Rop protein is facilitating loop-loop interactions between 
both RNA species and, thus, is directly regulating replication frequency and PCN. 
They could also show experimentally that Rop binds specifically to RNAI and RNAII 
stem sequences (and therefore prevents RNAI and RNAII from RNase-mediated 
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digestion) but they failed to identify the nucleotides that are involved in the 
interaction. However, they have no proof that the ratio of Rop, RNAI and RNAII is 
1:1:1 ratio but several models propose that a number of Rop proteins are to be found 
in the complex. It is also proposed that the Rop protein is dissociating subsequently 
after formation of the complex (17).  
 
 
Fig.2: According to structural analysis of the Rop protein, it consists of two helices (helix I in red and 
helix II in blue). Amino acid residues, involved in RNA binding, are shown in yellow. (B) Loop-loop 
interaction of RNAI-RNAII leads to formation of minor and major groove (adapted from 
www.marinolab.umbi.umd.edu). 
 
In vivo and in vitro studies have demonstrated that Rop is not acting as a repressor 
as initially thought rather it enhances RNAI inhibitory activity (Cesareni et al., 1984; 
Lacatena et al., 1984).  
In 1984, Tomizawa and Som could show that Rop increases and accelerate 
RNAI and RNAII hybridization. Therefore they renamed Rop to Rom (“RNA One 
Modulator”) due to its newly observed function. Though, Rop/Rom is not the only 
factor involved in regulation of the RNAI-RNAII hybridization. According to current 
findings the initiator protein of the ColE1-unrelated plasmid R6K and the avian 
retroviral NBP.P12 protein can regulate the hybridization of the two RNA species as 
well (16). pBR322 and its derivatives applied in the molecular biology field contain 
the ColE1-type origin but lack the Rop encoding gene frequently. ColE1-type 
plasmids and its derivatives like pBR322 are low-copy plasmids (about 15 per cell). 
Deleting the rop encoding gene, PCN is increased 3-4 times (25). 
1 Introduction 
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1.1.2 Inheritance of bacterial plasmids 
Resolution of plasmid oligo- or multimers into monomers, regulated plasmid 
partitioning and killing of plasmid-free descendents are evolved mechanisms 
essential for stable maintenance of bacterial plasmids (12). 
 
1.1.3 PCN control 
Any plasmid has a specific copy number in different bacterial species. The initiation 
of replication, and thus PCN, is regulated by plasmid-encoded elements. To stably 
coexist with its host, guarantee stability, maintenance and to reduce the metabolic 
burden to a minimum extend, plasmids must develop subtle mechanisms to control 
their replication (Del Solar et al., 2000). To maintain and “sense” the copy number, 
plasmids implement negative regulatory mechanisms. To be established in the new 
host, the concentration of the negative regulators is insignificant in this context. This 
seems to be essential since uncontrolled plasmid replication favours normal copy 
number immediately. After achieving a specific copy number, it has to be maintained 
or adjusted to fluctuations by increasing or decreasing the frequency of replication 
per plasmid copy. Thereby, randomly chosen plasmids are selected for replication. 
However, plasmids with the same replicons can not be maintained in the same host 
without selective pressure (Del Solar et al., 1998). Mechanisms such as 
hemimethylation and supercoiling facilitate identification of newly synthesized 
plasmids (21, 26). 
 In response to fluctuations, E. coli evolved different mechanisms to control and 
maintain the PCN: (i) directly repeated sequences (iterons); (ii) binding of antisense 
RNA to essential RNAs (termed countertranscribed RNAs or ctRNAs); and (iii) 
antisense RNA in combination with a protein, which can play either an auxiliary or a 
regulatory role. Especially in Gram-positive bacteria and for few rolling circle-
replicating plasmids and theta-replicating plasmids the third type of mechanism 
prevails.  
 PCN in R1- and ColE1-type plasmids is mainly maintained and regulated by 
ctRNAs and negatively regulating proteins such as Rom/Rop (21). ColE1-type 
plasmids and its derivatives are popular tools for cloning and transgene expression 
1 Introduction 
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since they are small in size and for replication they utilize host-encoded enzymes 
(19). 
 
1.1.4 Plasmid segregation in E. coli 
According to Gordon et al., replication of the single E. coli chromosome starts at a 
unique ORI and proceeds bidirectionally until the termination site is reached. In E. 
coli and in Bacillus subtilis this process is finished after approximately 40 minutes at 
37°C and both, the old and newly synthesized chromosomes are partitioned between 
the mother and daughter cell. Although the partitioning systems works highly 
accurate, chromosomeless cells occur with a frequency of less than 10-4. However, it 
remains unclear if chromosomes are partitioned by either active or passive 
mechanisms. In bacterial cells there is no proof for the existence of the mitotic 
apparatus, microtubules or microtubule-like structures as it is well known for 
eukaryotic cells. To test chromosome and low-copy plasmid segregation in E. coli, 
Gordon et al. engineered chromosomes containing tandem lac operator sequences 
close to the ORI as well as plasmids P1 and F.  
 Due to the expressed green fluorescent protein (GFP)-LacI fusion protein the 
partitioning process of chromosomes and plasmids could be followed by fluorescent 
microscopy. According to their gained results both, chromosomes and plasmids differ 
in their partitioning behaviour since they are differently localized within the cell. In 
contrast to the chromosomal oriC region, which stays in touch with the cell pole 
throughout the entire “cell cycle”, the plasmids P1 and F associate quickly with the 
site of septum after their replication. After chromosomal duplication, one 
chromosome continues its association with the old pole and the other is transported 
to the new cell pole (20). 
 
1.2 Gene therapy 
Since genetics proceeded in the 1980s, gene therapy opened a new avenue to treat 
genetic defects. The identification of genetic abnormalities that effect inherited 
diseases make the progress of gene therapy possible. Since clinical trials indicated 
that genetically inherited diseases (such as intestinal cancer, heart disease, diabetes 
etc.) are passed on to next generation family members gene therapy seems a 
1 Introduction 
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promising tool for its treatment. However, not only genetic defects but also 
environmental factors may affect many diseases and health conditions but it is safe 
to say that genetic defects make living organisms even more proned to it and that 
most diseases have a genetic cause.  
 In contrast to DNA vaccines, whose intentions are to stimulate the immune 
system of an individual within a short time, gene therapy is usually targeted at 
persisting expression of the therapeutic gene avoiding stimulation of the immune 
system. Sometimes, gene therapy is directed at incorporation of the therapeutic gene 
into the host's chromosome. Unlike DNA vaccines, the therapeutic DNA must be 
internalized by the target cells and guarantee it’s finely tuned and long-lasting activity 
when gene therapy is applied. For that reasons gene therapy has not yet achieved 
success as DNA vaccines did. However, application of gene therapy is focussing on 
different purposes: (i) the therapeutic gene is encoding proteins to exert new 
functions in the patient’s cell or to restore the function of mutated proteins; (ii) the 
therapeutic gene aims to knock down or off the expression of a default gene (38).  
For now, both DNA-based (in vivo) treatments and cell-based (ex vivo) 
treatments are objects of intense research in the United States. The transfer of the 
therapeutic gene to the host’s cells can be conducted by applying vectors including 
viruses or pDNA (“DNA-based gene therapy”). Cell-based gene therapy is 
characterized by taking patient’s cell from the body to restore dysfunctional genes in 
vitro and to return the restored genes to the patient’s body. Clinicial trials for the 
treatment of cystic fibrosis (using adenoviral vector), HIV (Human immunodeficiency 
virus) infection (cell-based), malignant melanoma (cell-based), kidney cancer (cell-
based), Gaucher's Disease (retroviral vector), breast cancer (retroviral vector), and 
lung cancer (retroviral vector) has been conducted until now (14).  
At the beginning of gene therapy scientists brought in genes directly into 
human cells to repair single-gene defects causing cystic fibrosis, haemophilia, 
muscular dystrophy and sickle cell anemia. This approach has turned out to be more 
difficult as initially thought since the therapeutic gene prefers recombining randomly 
in the host genome instead of replacing the dysfunctional gene (36). 
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1.2.1 Classification of gene therapy 
Gene therapy may be classified into two types: 
Germ line gene therapy 
Reproductive cells (sperm or eggs) are genetically modified to correct inherited 
genetic defects and the manipulated genome would be transmitted on to the next 
generations. However, germline therapy would have a lasting effect on the gene pool 
of the human species. Current laws have put a ban on this kind of application in 
human beings for ethical and technical reasons. 
 
Somatic gene therapy 
Somatic gene therapy targets at modifying the genome of the somatic cell and is 
restricted only to the person treated with gene therapy. The genetic modification will 
not be transmitted to the next generations. 
 
1.2.2 Vectors used in gene therapy 
1.2.2.1 Viruses 
Viral vectors 
Viruses attach and transfer their genetic material into their host cells. To ensure 
replication of viral DNA they hijack the host’s cellular machinery. Consequently, the 
host cell will produce many copies of the virus leading to increasing infection of 
uninfected cells. To become a permanent component of the host’s chromosome 
some specific viral types evolved mechanisms to insert their genetic material. 
 
Retroviruses 
Retroviruses introduce their ribonucleic acid (RNA) including the reverse 
transcriptase, integrase and other enzymes into the cell. Subsequently, the RNA 
molecule is reverse transcribed to DNA (known as copy-DNA or cDNA) promoted by 
the reverse transcriptase. The viral cDNA must enter the nucleus of the host cell by 
using specific mechanisms to be chromosomally integrated catalyzed by the 
integrase. Division of the host cell will pass this recombinant genome on to its 
descendant cells. It can be assumed that insertion of viral genes can occur randomly 
into the host's genome leading to insertional mutagenesis or even to uncontrolled cell 
1 Introduction 
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division. Strategies such as the design of zinc finger nucleases and insertion of 
specific sequences such as the beta-globin locus control region to facilitate site-
specific integration should circumvent this problem. Sometimes gene expression of 
the retrovirus takes place at a later time. 
 In the year 1999, 11 boys with X-linked severe combined immunodeficiency 
(XSID), also known as “bubble-baby syndrome”, were treated with their own bone 
marrow, which previously was transduced with retroviral vectors to restore the 
deficient Adenosine Deaminase (ADA) allele (fig.3). XSID is known to be a X-
chromosomal linked disease characterized by a rare and disastrous immune 
disorder. For years, this gene therapy represented a story of success, the immune 
system was restored but in 2002 2 of the 11 patients came down with a leukemia-like 
disease. This is probably due to insertional mutagenesis close to the oncogene LMO-
2 which is known to provoke several human T cell acute lymphoblastic leukemias (T-
ALL). Authorities prohibited temporarily this clinical trial together with similar gene 
transfer trials but the hypothetical risk of random integration into potentially harmful 
sites has been estimated to be low (Kay et al., 2001). In 2002, after protocol review, 
clinical trials were continued in the United States, the United Kingdom, France, Italy, 
and Germany. According to significant hints development of the leukemia-like 
diseases may have been disease- and protocol-specific. 
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Fig.3: Procedure of cell-based gene therapy. (1) Vectors, mostly crippled viruses, are used as vehicles 
to transfect patient’s cells with the therapeutic gene. (2) Isolated bone marrow cells from the patient 
are transfected ex vivo with the virus. After viral transfection the patient receive transplants of his own 
bone marrow. (3) Repaired cells restore the patient's immune system (5). 
 
Adenoviruses 
Adenoviruses contain a ds DNA. Usually, they cause respiratory (such as common 
cold), intestinal, and eye infections in humans. The DNA of the adenovirus is neither 
inserted into the host cell's genome nor is replicated when the replication of the 
eukaryotic genome is induced, thus leading to transient gene expression. Therefore, 
successful treatment needs readministration. In China, Gendicine, an adenovirus 
vector harbouring the tumor suppressor gene p53, is the first gene therapy product to 
treat cancer and was permitted by the Chinese Food and Drug Administration (FDA) 
in 2003 to cure head and neck cancer. Application of Gendicine together with 
chemotherapy and radiotherapy could cure cancer to some extent. By contrast, 
Advexin, a similar gene therapy administration from Introgen, was denied by the US 
FDA in 2008. The death of Jesse Gelsinger, a patient participating in a gene therapy 
trial, caused distrust about the safety of adenovirus vectors leading to preferential 
treatment with genetically crippled viruses. 
 
Adeno-associated viruses 
Adeno-associated viruses (AAV) are small viruses containing single stranded (ss) 
DNA. The wt type AAV can incorporate DNA site-specifically whereas the 
recombinant AAV, which is harbouring only the therapeutic gene, does not integrate 
into the host's chromosome but is producing episomal forms by recombination. 
These “episomes” guarantee expression of the therapeutic gene in the long run. 
However, AAV's largest disadvantage as a gene therapy vector could be its low 
packaging capacity due to the limited size of the AAV virion and technical problems 
in its manufacturing. AAV is non-pathogenic and, in contrast to wt adenoviruses, it 
will not be removed by the host's immune system. Nowadays, AAV vectors are used 
in clinical trials to treat muscle and eye diseases as well as cerebral diseases since 
dormant cells (such as neurons) are target cells of AAVs as well.  
 The retroviral encoded env gene facilitate recognition of cells which represent 
a specific receptor on their surface (Adams et al., 1995). So, in contrast to 
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adenoviruses and adeno-associated viruses, retroviral infection is limited to specific 
cells. 
 
Replication Vectors 
Retroviral vectors are known to be either replication-competent or replication-
defective. ONYX-015 (previously called CI-1042) is a replication-competent vector 
modified to replicate in and induce rapid apoptosis in cells harboring p53 mutations. 
Replication-defective vectors with multiple deletions of essential genes infect their 
target cells but after transgene delivery cells will undergo lysis and death. 
 
Cis- and trans-acting elements 
Replicative-defective vectors contain always a “transfer construct” including the 
transgene as well as the packaging sequence, sequences for replication and, 
sometimes, sequences for reverse transcription. Thus, these sequences are 
characteristic cis-acting elements, they contain viral sequences on the same 
chromosome in contrast to the viral trans-acting elements, which can be located not 
only on the same DNA. 
 
Herpes Simplex Virus 
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are members of the Herpesviridae 
family known to infect humans. The wt HSV-1 can infect neuronal cells, which are 
usually ignored by the immune system after infection. 
 Many worries arose since an attenuated viral strain could revert to its 
pathogenic version (Clark et al., 2008) making gene therapy applications with live 
viruses even complicated. Some specific live viruses can even circumvent or 
suppress the immune response. 
 
1.2.2.2 Non-viral methods 
Oligonucleotides 
Therapeutic oligonucleotides are used in gene therapy to silence the expression of a 
gene, causing a particular disease, on its transcriptional or translational level. 
Oligonucleotides include the synthesis of nucleic acids of DNA, RNA or chemical 
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analogues to knock down or knock off a disease causing messanger RNA (mRNA). 
However, antisense therapy (such as applications with siRNAs) is a way to treat 
genetic disorders or infections but is not strictly a kind of gene therapy. Another 
strategy uses ds oligodeoxynucleotides to titrate transcription factors from the 
promoter of the default gene leading to decreased expression rates. Furthermore, 
application of ss DNA oligonucleotides targets at induction of a single-base pair 
mutation within the disease-causing gene (“targeted gene repair or targeted 
nucleotide alteration”). 
 
Lipoplexes and polyplexes 
Lipoplexes (DNA complexed with cationic lipids) and polyplexes (DNA complexed 
with synthetic polycationic polymers) aim at efficient delivery of DNA into the patient’s 
cells and stabilizing DNA by preventing its degradation. However, DNA-lipid 
complexes form structures such as micells or liposomes.  
 In contrast to cationic lipids, the elaborating production of anionic and neutral 
lipids was neglected. Several features making cationic lipids (because of their 
positive charge) a proper tool in biopharmaceutical applications such as association 
with and condensation of the negatively charged DNA, formation and stabilization of 
lipoplexes and facilitate uptake due to higher affinity to the cell membrane. Still, 
cationic lipids can cause toxicity in a dose dependent manner making them 
unsuitable for gene therapy purposes.  
 Mostly polyplexes can not set their DNA cargo free into the cytoplasma. 
Therefore, cotransfection with endosome-lytic agents is necessary. Since polymers 
such as polyethylenimine have intrinsic endosomal activity, they can trigger 
endosome destruction as well.  
 
Hybrid methods 
Some gene transfer techniques are combined such as virosomes (derived from 
inactivated HIV or influenza virus) complexed with liposomes. It has turned out that 
virosomes can overcome the epithelial airway barrier easier than application of viral 
or liposomal methods alone. Viral vectors complexed with cationic lipids or 
hybridising virus could be used as alternatives in gene therapy applications as well.  
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Dendrimers 
A dendrimer is a spheric synthetic macromolecule which is highly branched. 
Recently, it has been observed that the use of highly branched macromolecules has 
significant effects on gene therapy success in contrast to the traditionally used linear 
polymers. The positive charge of cationic dendrimers enhances its complextion with 
the negatively charged DNA and the dendrimer-nucleic acid complex may then be 
internalized by a clathrin-dependent endocytosis (36). 
 
Synthetic vehicles (SV) 
For the improvement of therapeutic approaches, synthetic delivery systems are 
considered promising tools as non-viral vehicles. Chemical bonds of the non-viral 
vector are only cleaved in response to various stimuli such as environmental or 
external triggers. Using masked endosomolytic agents (MEAs) is one example for 
this approach: a pH-labile bond of the vector is only opened when MEAs are entering 
the acidic endosome. Subsequently, the nucleic acids must be released from the 
endosome to avoid its lysosomal degradation. Similar to the delivery methods 
mentioned in 1.3.4, SVs can be used to transport pDNA in vivo as well. Recently, 
MEA-dynamic PolyConjugates (DPCs) have been used as vehicles in clinical trials to 
provide hepatocytes with siRNAs in vivo. (42). 
 
Naked DNA 
Unlike viruses, plasmids are "naked" DNA used as gene medicine or DNA vaccine to 
fight viral, bacterial, parasitic diseases, or cancer (57). Transfection of cells with 
naked DNA is the easiest method of non-viral transfection since pDNA is chemically 
simple, easy to produce and characterize, and host cells can be transfected either 
with naked pDNA, coated with gold or as lipid-DNA complexes (Ledwith et al., 2000). 
 
1.2.2.3 Bacterial gene transfer vectors 
Since lately, the bacterial gene transfer vector has been proposed as a third type of 
vector to be used in gene therapy. Bacterial strains such as Salmonella, Shigella, 
Listeria, Yersinia, and E. coli could be qualified for the use as a vehicle for the 
therapeutical gene. Although the mechanism of how the DNA is passed on from the 
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bacterial cell to the mammalian cell is yet not clear but in vitro and in vivo studies 
demonstrated it definitely (fig.4) (43). 
 
 
Fig.4: Different methods of application in gene therapy. After removal and in vitro transfection of host 
cells, the “repaired” cells are then returned into the patient’s body. Replication deficient and attenuated 
virus or bacteria deliver the therapeutic gene via transfection of the host cell. Alternatively, cells are 
transfected with pDNA by using different delivery methods (31). 
 
1.2.2 Optimization of plasmid vectors 
According to Carnes et al. the production of highly pure pDNA for applications in 
gene therapy starts with prudent considerations about (i) the rational design of the 
plasmid vector, (ii) plasmid composition, (iii) yield and quality, and (iv) purity after 
downstream processing, to be approved by regulatory authorities (13).  
 It is a fact that PCN is correlating with the choice of the ORI. In general, pDNA 
for therapeutic purposes contain the ColE1 or pMB1 ORI but, according to Carnes 
the use of pMB1-derived pBR322 plasmids with a G-to-A mutation or the truncated 
origin in pUC derived plasmids such as p15A multiplicate the PCN. In small scale 
fermentations temperature-sensitive origins occurring in pMM1, pMM7 and pUC are 
preferred because PCN can be increased 30- to 40-fold after temperature rise from 
30°C to 42°C (10, 44). However, it could be clarified that the G → A transition in the 
ORI of pUC vectors leads to minor or even no loop-loop interaction between RNAI 
and RNAII because the point mutation somehow influence the proper folding of the 
RNAII (Lin-Chao et al., 1992; Herman et al., 1994). Furthermore, the Rom/Rop 
protein or a drop in temperature finally leads to normal plasmid concentration. To 
sum up, the temperature-sensitive G → A transition can be employed on any 
pBR322-derived plasmid to multiply pDNA production enormously (33). 
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1.2.2.1 Rational vector design 
The demand for large quantities of highly pure pDNA is arising since gene therapy 
and DNA vaccines are playing more and more a central role in preclinical studies. 
The field of therapeutic application of pDNA (DNA vaccines, DNA replicon vaccines, 
short hairpin RNA (shRNA) vectors, AAV helper plasmids, therapeutic plasmids, 
gene targeting plasmids) is broad including prevention (viral, bacterial, or parasitic 
diseases), immunization, therapeutic vaccination (infectious diseases, allergy, 
autoimmunity), cancer vaccination, or its use as gene therapy vehicles. In contrast to 
conventional vaccines, new pDNA vaccines can be designed and produced to be 
applied against new biological pathogens (13) within a short time instead of years. 
As a shuttle vector pDNA has to fulfil standardized criteria such as elements 
essential for its upkeep and reproduction in the bacterial and mammalian host as well 
as elements crucial for expression of the target gene in the human or animal host (4). 
Construction of pDNA vectors, which are to be used in gene therapy or DNA vaccine 
applications, requires observance of certain criteria in the course of its rational 
design. Thus, pDNA vectors have to obtain: (1) a constitutive, inducible, or tissue-
specific promoter with transcriptional activity and a transcription terminator; (2) 
elements necessary for optimized mRNA processing and translation inclusively 
Kozak sequence, translational termination, mRNA cleavage, polyadenylation and 
mRNA-splicing sites; (3) prokaryotic ORI for propagation in E. coli; and (4) selection 
marker for maintaining and positive selection of cells harbouring the pDNA or, 
alternatively, antibiotic-free selection mechanisms (fig.5). All these pDNA 
components should be reduced as much as possible to obtain vectors, which vary 
between 3 and 12 kb without the gene of interest (GOI). Furthermore, in the course 
of time it became apparent that removing toxic or disturbing sequences from the 
vector have a beneficial effect on pDNA production. To sum up, the rational vector 
design is affecting both the production of pDNA and its effective application (2). 
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Fig.5: Vector design strategies. For accumulation of pDNA in E. coli, selectable markers such as the 
kanamycine resistance (KanR) or alternatively, antibiotic-free selection mechanisms, and the pUC ORI 
(whereas other ORIs could also be used) are crucial. In the mammalian system, eukaryotic elements 
such as the promoter/enhancer, the transgene, and polyadenlyation signals are playing a key role in 
the design of a pDNA vector (7). 
 
Production of plasmid-encoded pharmaceuticals requires specific design of 
bacterial strains and plasmids. Improvement of plasmid stability, advancement of 
product safety, accumulation of plasmid amount and simplification of downstream 
purification processes are getting central objects of strain and vector engineering. At 
present, for pDNA production E. coli strains and plasmid backbones are used that 
are not specifically suited for production of pDNA. Overall, bacterial strains and 
pDNA design require alterations to maximize copy number, genetic fidelity, and 
segregational stability (7). 
 
1.2.2.1.1 Antibiotic-free selection systems 
For the propagation, maintenance and selection of recombinant cells, antibiotics and 
antibiotic resistance genes have been the single choice for a long time. However, 
their use in gene therapy or other biotechnological fields is more than questionable. 
For safety reasons, WHO, FDA and the American federal regulation strongly advised 
against the use of antibiotics and antibiotic resistance genes to prevent undesirable 
spread of antibiotic resistance in non-resistant bacteria. Constant expression of the 
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resistance protein is a heavy metabolic burden for the host cell and the antibiotic 
itself contaminate the final product. Several experiments made clear that removing 
bla (or other antibiotic resistance genes) and other sequences from therapeutic 
plasmids enhance expression of the transgene clearly and promote pDNA stability 
and yield in the fermentation process. Furthermore, some patients are hypersensitive 
to β-lactam antibiotics causing allergic reactions even up to anaphylaxis.  
 Circumventing the use of conventional antibiotics makes sense for several 
reasons since resistant bacteria fail to respond, antibiotics are unsuitable for vaccine 
production and expensive for industrial scale production (Goh et al., 2008). As a 
result, antibiotic-free selection systems are objectives of research and development 
and recently many antibiotic-free selection systems are patented. However, non-
antibiotic systems demand mutant host strains, specific media or expensive 
reagents. In the first known antibiotic-free selection system only those auxotrophic 
bacteria could grow on specific media whose defect gene was complemented by a 
plasmid-encoded gene. Repression-titration is another method avoiding the use of 
antibiotics and antibiotic-resistance genes where the lac operator “de-represses” an 
endogenous essential gene.  
 
 
Fig.6: Strain design strategies. The E. coli parent strain, presented here in the model, can be any E. 
coli K-12 strain. Gene knockouts, the use of antibiotic-free selection systems, genomic reduction, 
removal of mobile elements and, expression of heterologous nucleases to degrade host genomic DNA 
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(gDNA) and RNA after cell lysis are just a few strategies to engineer strains to be used for the 
production of pDNA (7). 
 
1.2.2.2 DNA Structure 
Besides its canonical Z-form and B-form, DNA can adopt conformations which are 
known as the noncanonical A-DNA-, C-DNA-, D-DNA- and E-DNA-form. 
Consequently, for gene therapy only the canonical B-DNA form is relevant since 
specific DNA structures and sequences can cause instability problems (2). However, 
the rational vector design requires a clear understanding of both the DNA sequence 
and DNA structure.  
 
1.2.2.3 Transformation efficiencies 
According to Kreiss et al. the uptake of pDNA into the nucleus across the nuclear 
pore complex is influenced clearly by its size. Experimental data demonstrated that 
transformation with larger plasmids such as the P1 artificial chromosome (PAC) 
decreases transfection efficiency significantly in contrast to small vectors. Walker et 
al. investigated that the PAC vectors showed lower transformation rates resulting in a 
consequent lower expression rate of the GOI. However, these effects demand further 
explanations (35). Furthermore, for pDNA endolysosomal inclusions and 
degradation, cytosolic sequestration, nuclear exclusion of pDNA, and metabolic 
degradation are further obstacles to overcome (Lechardeur et al., 2004). 
 Many barriers provide a biological hindrance to the entry of exogenous DNA 
including the extracellular matrix, the endosomal/lysosomal environment, the 
endosomal membrane, and the nuclear membrane making the application of non-
viral gene therapy difficult. However, the permeability of the nuclear membrane itself 
impeding the successful entry of pDNA especially in non-dividing cells where the 
nuclear envelope is not dissolving due to missing mitosis. However, Dean et al. could 
show experimentally that the 72-bp repeats of the SV40 enhancer is a clear benefit 
for the delivery of pDNA into the nucleus whereas the activity of the promoter and the 
ORI are insignificant for the its nuclear localization (44). 
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1.2.2.4 Plasmid stability 
It is safe to assume that specific sequences somehow negatively affect the 
production of supercoiled plasmids, which are recommended by FDA to prevail in the 
fermentation process. AT rich regions are proned to the host ss nucleases leading to 
nicking. Repeats as well as direct or inverted palindrome sequences are affecting 
pDNA stability in batch fermentation. The same is true for Z DNA-forming sequences 
such as CpG repeat sequences or formation of multimers. Dimerization of pUC 
plasmids is promoted by oligopyrimidine or oligopurine sequences leading to 
unconventional DNA conformations such as triple helices.  
 However, factors causing segregational instability, such as plasmid size, 
promote formation of plasmid-free-cells (Mathur et al., 2009). Many high copy 
plasmids are irregularly disseminated between descendant cells since they lack 
controlled partitioning systems. Furthermore, high-copy plasmids can overwork the 
metabolism of their host providing plasmid-free cells with a growth advantage within 
a fermentation process (10, 13). 
 According to Yamaguchi et al., OriC-containing plasmids cannot be stably 
maintained in specific recA strains of E. coli (due to incompatibility) unlike other E. 
coli recA strains. In many cases it has been noticed that plasmids, having an 
evolutionary ancestor in common, cannot co-exist in the same host cell and exclude 
each other (Chakrabarty, 1973). This process is called “incompatibility”. It appears 
that the quantity of determinant(s), responsible for incompatibility, is directly involved 
in the loss of plasmids (15). 
 
1.3 DNA Vaccines 
1.3.1 Definition of DNA vaccines 
According to the definition of FDA DNA vaccines are highly purified plasmids 
encoding antigens to protect individuals against infectious agents by boosting and/or 
triggering efficient immune response. In 1990, Wolff et al. were among the first 
suggesting the idea of DNA vaccination. The idea was to synthesize the antigen, 
delivered by the pDNA molecule, directly in the target organism to stimulate the 
immune system. To do so, they injected the pDNA-encoded antigen into murine 
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skeletal muscle. Since then, DNA vaccination is an object of intense research but 
some DNA vaccine trials have failed due to inappropriate transgene expression (48). 
 To date, various diseases have not been kept under control by conventional 
vaccines. Millions of people succumb to fatal diseases every year such as HIV/AIDS 
(Acquired Immune Deficiency Syndrome), malaria, cancer, and many others. 
However, viral vectors and DNA vaccines are only used in preclinical trials and 
currently there are no DNA vaccines as licensed products available (31). Hitherto, 
FDA has permitted DNA vaccine applications for various infectious diseases such as 
malaria, Hepatitis B and HIV in phase 1 clinical trials (9).  
 According to Krishnan, pDNA vaccines provide numerous advantages in 
contrast to conventional vaccines, such as (i) ease of production, (ii) stability and 
transport, (iii) no cultivation of pathogens, (v) vaccination against multiple pathogens 
in a single dose (48). 
 
1.3.2 The immune response to DNA vaccines 
DNA vaccination seems to be attractive since both arms of the immune system are 
involved (Jechlinger, 2006). Complex intracellular and intercellular interactions are 
necessary for an antigen to promote antibody production and cellular/humoural 
responses (see fig.7). Recombinant proteins or inactivated virus vaccines fail to 
stimulate the cytotoxic T lymphocyte (CTL) response, important for an immune 
response, because in the endolysosome the antigen is degraded into peptides which 
are incorporated subsequently into major histocompatibility complex (MHC) Class II 
molecules. T-helper cells (TH cells) are specifically induced by the peptide-MHC-
conglomerate important for both antigen recognition and initiation of immune 
response.  
However, to induce CTL response, association of peptides with MHC Class I 
molecules are essential. Finally, these MHC Class I-peptide complexes are detected 
by specific cytolytic T cells that trigger complete destruction of the infected cell. Thus, 
the idea in DNA vaccine technology is to induce CTL production by expressing 
antigenic fragments in the MHC Class I receptor leading to apoptosis of the infected 
cell (31, 45). 
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Fig.7: Mechanism of antigen-specific humoural and cellular responses. Professional APCs recognize 
exogenous antigens and induce its degradation to peptides which are then presented on the surface 
of MHC Class II molecules. The antigen peptide/MHC Class II conglomerate is detected by specific 
helper T cells (CD4+ T cells) which will be activated subsequently. Activated CD4+ T cells secrete 
cytokines to activate B cells and amplification of CTL responses. After recognition of peptide-MHC 
Class I complexes, presented by APCs, CTL (CD8+ T cells) are activated and induce apoptosis of the 
infected cell. After detection of extracellular antigens, B cells induce antibody production (31). 
 
 
1.3.4 Delivery methods 
Various delivery methods have been developed to improve and/or ease pDNA 
applications: 
(i) Ballistic delivery or “Gene-Gun delivery” facilitate gene transfer into a broad 
range of targets and is supposed to stimulate immune response most 
efficiently. In contrast to injections via syringes, applications with gene-guns 
are repeatable due to controlled adjustment of gas pressure and do not cause 
pain. 
(ii) Delivery by liposomes: injection, oral or intranasal absorption of cationic 
liposomes that include pDNA molecules 
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(iii) Electroporation-assisted delivery: In the first step, nucleic acids are injected in 
muscle or skin and to speedup pDNA molecules as well as to promote their 
uptake, an electric current is applied by using electrodes. 
(iv) In vitro transfection 
 Among various delivery methods for DNA vaccines, two approaches are 
currently favoured: injection via a syringe or application of gene gun technique. The 
mechanism of nucleic acid uptake is still not clear, but it is suggested that DNA 
uptake occurs via caveolae and/or might involve keratinocytes, fibroblasts and 
epithelial Langerhans as well, which migrate quickly to regional lymph nodes (Lewis 
et al., 1999). Furthermore, phagocytosis and/or pinocytosis or specific receptors like 
a 30 kDa surface receptor or a macrophage scavenger receptor could also play a key 
role in DNA uptake.  
 In DNA vaccine applications, intramuscular injections are favoured because 
muscle cells are considered to take up DNA highly efficient but they fail to generate 
immune response since they are no professional APCs (31, 32, 46). 
 
1.4 Problems and ethical aspects of gene therapy and DNA 
vaccination 
In gene-based therapy, opinion about the Weissman barrier is divided on its safety 
issue because, according to this theory, genetic information is only passed on from 
germ line cells to somatic cells and never the other way round (Sullivan). However, if 
this soma-to germ line barrier does not exist than genetic information, derived from 
gene therapy, can be spread to germ cells (“germline transmission”), and would lead 
to a change in the genetic pool of the human species.  
 Current problems of gene therapy involve: 
• Short-lived nature of gene therapy – the therapeutic DNA must persist in the 
patient’s cells, expressed at constant levels, and cells harbouring the 
therapeutic gene must be stable and long-living to be profitable for the patient 
in the long run.  
• Theoretical concerns rise since therapeutic genes can be randomly inserted 
into the host’s genome leading to activation of oncogenes or inactivation of 
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tumor suppressor genes. In addition, insertion might lead to chromosomal 
instabilities by breaking or rearranging DNA.  
• Reduction in efficacy of the gene therapy effect – Invaders that already 
induced immune response are recognized faster by the immune system after 
a second infection. Thus, using e.g. viral vectors in gene therapy seem 
impossible when repeated in patients. 
• Problems with viral vectors – Viruses used in gene therapy trials can cause 
problems such as toxicity, immune and inflammatory responses. Since 
attenuated viral strains could revert to wt their use in gene therapy, to treat 
specific viral infections such as HIV, is doubted. Furthermore, some viral 
species evolved strategies to escape or downregulate the host immune 
response. 
• Multigene disorders – Frequently emerging genetic diseases are multifactorial 
such as heart disease, high blood pressure, Alzheimer's disease, arthritis, and 
diabetes (36).  
• In transient expression assays David Peterson et al. identified sequence 
elements within pBR322 that negatively influence expression of eukaryotic 
transgenes in cis. This region interferes with a negative element, a poison 
sequence that is known to inhibit DNA replication. Furthermore, Courey et al. 
announced that specific pBR322 sequences can downregulate the activity of 
the human β-globin promoter. Peterson et al. considered these negative 
elements to act as silencers on eukaryotic genes (47). 
 
1.4.1 Potential safety concerns of DNA vaccines 
According to Hodgson et al., careful consideration and questioning is necessary 
when it comes to pDNA applications in humans depending on approval of WHO, US 
FDA, or European Agency for the Evaluation of Medicinal Products (EMEA) (57). 
 Preclinical studies imply that after DNA vaccine application glycoprotein 
immunoglobulin G (IgG) anti-DNA autoantibodies are secreted due to activated 
autoreactive B cells but it is unlikely that systemic autoimmunity is generated by DNA 
vaccination. Concerns are raised that organ-specific autoimmunity could be induced 
or even declined after DNA vaccine application (9). 
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 Experiences gained by veterinary DNA vaccines might be useful for human 
DNA applications. Though, reproduction of immune responses, noticed in animal 
models, in humans is not possible in general but many approaches have been made 
to improve the human immune response such as enhanced uptake, stabile 
expression, modulation of the immune response, or in adjuvanting (49).  
 
1.5 Strategies to increase plasmid concentration by overexpression 
of rssB and tRNAAlaU 
1.5.1 rssB leading to enhanced ColE1 PCN in pcnB mutants 
By screening multicopy library harbouring randomly integrated chromosomal 
fragments in pcnB mutants, Jain et al. found the rssB encoding gene that significantly 
increased ColE1 PCN after its induced overexpression. So far, the mechanism how 
rssB might regulate PCN remains unclear. In E. coli, PcnB shows its homology to the 
cca gene encoding the tRNA nucleotidyltransferase which binds tRNA. So, one might 
guess PcnB might be an RNA-binding protein. By binding to RNAI, it blocks the 
RNAI-RNAII hybrid formation finally leading to enhanced plasmid replication. 
Alternatively, after sequence analysis Cao and Sarkar identified the pcnB locus to be 
homologous to the E. coli poly(A) polymerase I (PAP I) which catalyzes 
polyadenylation of RNA. So, polyadenylated RNAI is unable to bind RNAII because it 
is proned to degradation. Deletion of PAPI showed that RNAI intermediates are 
strongly accumulating within the cell leading to decreased pDNA replication and, 
thus, decreased PCN of ColE1-type plasmids (He et al., 1993; Xu et al., 1993). 
However, PcnB is known to regulate plasmid replication since strains with deletion in 
the PcnB locus reduce PCN at very low levels and cause plasmid instability. 
 It is presumed that the pcnB defect is suppressed by overexpressing RssB 
either caused by PAPI-independent polyadenylation (such as the PNPase) of RNAI 
or by enhanced degradation of nonpolyadenylated RNAI species (Carabetta et al., 
2009). Carabetta et al. consider the PCN of ColE1-derived plasmids is clearly 
regulated by the RssB-PAPI collaboration (1, 50). It is known that RssB, the ClpXP 
protease and a cis-acting turnover element (somewhere between methionine 159 
(M159) and histidine187 (H187) are somehow involved in the controlled degradation 
of σS (a subunit of RNA polymerase in E. coli) (53).  
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1.5.1.1 RssB 
In E. coli, the master response regulator RssB (also known as SpreE or MviA) is an 
element of a two-component signal transduction pathway. The RssB protein is 
homologous to the N-terminal domain of the response regulator family, but its C-
terminal output domain is not homologous to any identified protein. However, 
depending on phosphorylation of the N-terminal RssB receiver domain RssB 
recognizes the turnover element (see 1.5.1) within σS (53). It is speculated that stress 
somehow stabilizes σS and promote inactivation of RssB by dephosphorylation of its 
receiver domain.  
Hitherto, two interaction partners of σS are known: (i) RNAP core enzyme; and 
(ii) RssB, which mediates σS degradation. It is worth noting that the binding site for 
RssB in σS is adjacent to the crucial – 10 promoter element. 
 Hengge-Aronis et al. could clarify experimentally that RssB can be an anti-
sigma factor for σS in vivo as well. When σS is accumulating, RssB can act as a 
repressor of σS-dependent genes (28, 29).  
 
Cis-acting element 
This cis-acting turnover element is to be detected somewhere between M159 and 
H187. By site-directed mutagenesis Gisela Becker et al. confirmed lysine 173 (K173) 
and the amino acids around as the turnover element in σS. Substitution of K173E 
(glutamate abbreviated as E) has turned out to prevent ClpPX-mediated proteolysis. 
However, K173 in σS has dual functions: it is essential for σS proteolysis but it may 
play a role in promoter recognition as well (53). 
 
ClpPX 
According to Muffler et al., it is not clear if σS degradation is catalyzed by either RssB 
itself or by the ClpPX protease, a complex ATP-dependent protease composed of 
proteolytic (ClpP) and chaperone (ClpX) subunits. However, there are hints that the 
protease is only active in the presence of RssB or that RssB might expose σS to the 
ClpPx protease machinery. Experiments in the near future will establish clarity (24). 
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1.5.1.2 Stability of RpoS/σS 
Lange et al. verified experimentally that rpoS/σS (σS, a subunit of RNAP, is encoded 
by RpoS) expression is enormously complex and is controlled on (i) transcriptional 
level; (ii) translation level; and (iii) protein stability. RpoS expression is governed by 
various extrinsically signals such as cAMP, ppGpp, cell density signals, osmotic 
signals, and starvation signals (fig.8.). Increasing medium osmolarity does not induce 
necessarily rpoS transcription but rather some post-transcriptional mechanisms. Not 
only σS is controlling stationary phase-induced gene expression but various 
regulating factors as well such as 3’, 5’-cyclic AMP-cAMP receptor complex (cAMP-
CRP) cAMP-CRP complex, Lrp and integration host factors. Each factor is revealed 
to be part of a complex regulatory network regulating expression of many genes 
induced in the stationary phase (27). Both, entry into stationary phase and increased 
medium osmolarity are enhancing RpoS translation intensely. However, in 
exponentially growing cells σS is a highly unstable protein with a half-life of 1.4 
minutes but its clearly more stable in stationary phase (~10.5 min) (27).  
 All in all, stress signals and transition into stationary phase bring about up-
regulation of RpoS and as a transcriptional activator it enhances transcription of 50-
100 genes leading to stress resistance and other physiological and/or morphological 
modifications (53). 
 
 
 
Fig.8: Model of regulation of rpoS/σS expression. Various extrinsically signals (indicated in the model) 
are regulating its expression on transcriptional, translational level as well as its stability (27). 
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1.5.2 Uncharged tRNAAlaU(UGC) in relA mutants 
tRNA is not only involved in translation, moreover novel functions has been revealed 
recently e.g. retroviruses and long terminal repeats (LTR) retrotransposons utilize 
priming tRNAs for reverse transcription (Marquet et al., 1995), in amino-acid starved 
E. coli tRNAs interact with RNAI and/or RNAII, thus regulating replication of ColE1-
type plasmids (Wróbel et al., 1997, 1998; Wegrzyn, 1999; Wang et al., 2002). 
Furthermore, it was shown that the T helper immune response in mice was stronger 
stimulated after application with tRNAAla adjuvants (Wang et al., 2006) (8).  
 It took many years, until a model for tRNA-dependent regulation of ColE1-like 
plasmids replications has been recommended by Yavachev and Ivanov. Before then, 
Hecker et al. were among the first stating that the copy number of the ColE1-like 
plasmid pBR322 was clearly enhanced in amino acid starved E. coli. 1994, Herman 
et al. declared that depending on what kind of amino acid was missing in the media, 
ColE1-type plasmids varied in their replication behaviour. The same is true for other 
ColE1-like plasmids (Wróbel and Wegrzyn, 1998). However, still it is not clear why 
lack of different amino acids result in different replication behaviour of ColE1-like 
plasmids. It has been considered that ppGpp, a global regulator of gene expression 
in bacteria, can somehow prevent replication of ColE1-like plasmids (Herman et al., 
1994) (55).  
 In 1988, Zavachev and Ivanov studied sequence similarity between all 21 
tRNAs and RNAI/II, encoded on the ColE1 plasmid. According to their homology to 
RNAI/RNAII, all tRNAs were divided into three classes: (i) tRNAs homologous to 
RNAI (Arg, His, Leu, Lys, Phe, and Thr); (ii) tRNAs homologous to RNAII (f-Met, Try, 
and Gly); and (iii) tRNAs homologous to RNAI and RNAII (Met and Val) (Zavachev et 
al., 1988). The anticodon loop of all tRNAs own seven nucleotides (Hjalt and 
Wagner, 1992) (18, 56). 
According to the model of Wang et al., RNAI-RNAII interaction could be 
hampered by accumulated uncharged tRNA present in bacterial cells during the 
relaxed response leading to enhanced plasmid replication. Other experiments argue 
for primer extension of the 3’ CCA sequence of uncharged tRNAs necessary to 
induce replication (Maizels and Weiner, 1994; Chen and Lambowitz, 1997) (55, 56). 
In 2006, experiments in amino-acid-starved RelA mutants (“relaxed response”) 
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suggested that uncharged tRNAAlaU(UGC) catalyze cleavage of RNAI leading to 
enhanced ColE1-like PCN in vitro and in vivo. The ACCA motif at the 3’-terminus of 
the tRNAAla (UGC) is crucial for cleavage of RNAI because those effects have not 
been seen when the 3’-ACCA sequence was deleted. Based on these data, Wang et 
al. assumed 3’-ACCA of tRNA together with the UGGU motif within the RNAI loops 
generate a catalytic structure capable of cleaving RNAI molecules only in the 
presence of Mg2+ ions. Want et al. stated that both, UGGU sequences and the 3’-
ACCA sequences may exert catalytic activity (8). 
 
1.5.2.1 Aminoacylation of tRNA 
Aminoacylation is a two-step process where a specific amino acid is attached to its 
cognate tRNA catalyzed by aminoacyl-tRNA synthetases (aaRS). To generate 
aminoacyl-tRNA molecules, ATP and the cognate amino acids have to bind to 
specific aaRS sites. After attachment, inorganic pyrophosphate (PPi) is released.  
To physically link the amino acid to the trinucleotide sequence of its cognate tRNA, 
the amino acid has to be transmitted from the aa-AMP to the 2’- or 3’-OH group of 
the 3’-end of the tRNA acceptor stem.  
 The 20 known aaRS differ in size, differ mostly in their sequences and can 
occur either as dimeric, trimeric or tetrameric complexes. The aaRS GlnRS, TyrRS, 
MetRS, GluRS, ArgRS, ValRS, IleRS, LeuRS, TrpRS belong to the class I having the 
conserved sequence motifs “HIGH” and “KMSKS” in common. According to crystal 
structures both motifs contain the Rossman fold, a nucleotide binding fold that binds 
ATP. Aminoacylation of the 2’-OH of an adenosine nucleotide is conducted by the 
class I synthetases. In contrast to class II synthetases, the class I molecules share 
two highly conserved sequence motifs. Class II synthetases contain three highly 
conserved sequence motifs and they catalyze aminoacylation of the 3'-OH of an 
adenosine nucleotide. Some synthetases conduct proofreading, a process to ensure 
highly accurate tRNA charging. Non-cognate amino acids are rapidly removed by 
hydrolyzation of the aminoacyl-tRNA bond (23, 58). 
 All 21 tRNAs have a trinucleotide sequence in their anticodon loop that can 
pair with several codons. To conduct correct tRNA aminoacylation, many aaRS do 
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not confide only in the trinucleotide sequence but utilize identity elements in the 
acceptor stem of the tRNA as auxiliary device as well.  
Recent experiments revealed that the G3•U70 base pair, located in the 
acceptor stem of tRNAAlaU, is an important but not solely identity element to be 
recognized by a cognate Alanyl-tRNA synthetase (AlaRS). According to McClain et 
al. the recognition mechanism of tRNAAlaU is both, directly and indirectly and not only 
catalyzed by AlaRS alone, but rather by several synthetases. Concluding from this, 
minihelices, duplexes, and smaller RNA helices, mimicking the acceptor stem, can 
be aminoacylated by AlaRS as well (59). 
To be recognized by the AlaRS, the first 4 bp encoded on the acceptor stem 
and the discriminator base A 73 of the tRNAAlaU molecule are critical as it has been 
shown in in vivo and in vitro experiments. According to that, base transversion in 
G2:C71, which is located close by the G3:U70 position, has a tremendous effect on 
recognition by AlaRS leading to a significant loss of aminoacylation activity. This is 
true for in vitro experiments (6).  
 
1.6 Chromosomal integration of linear DNA fragments via the Red 
Disruption System 
According to Lorenz et al. most bacteria refuse the uptake of linear DNA because it is 
consequently degraded by host encoded exonucleases. However, Datsenko and 
Wanner had the idea to amplify linear DNA by using PCR primers that are 
homologous to the target DNA region. To promote homologous recombination with 
linear DNA, the plasmid-encoded phage λ Red recombinase (fig.9) is necessary, 
which is controlled by the well-regulated OriR101 promoter. After shifting temperature 
to 42°C, pKD46 is simply excluded from the cells due to the temperature-sensitive 
ORI.   
Bacteriophages evolved their own homologous recombination system. In 
contrast to recD, recBC or sbcB mutants the recombination frequency was intensified 
when the Red-mediated recombination system together with linear DNA fragments 
was applied. However, the Red system encodes three genes, which are regulated by 
the ParaB promoter: γ, β and exo. After induction with arabinose, the final products 
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called Gam, Bet and Exo are expressed. The endogenous RecBCD exonuclease V is 
blocked by Gam facilitating recombination at DNA ends catalyzed by Bet and Exeo 
(3). 
 
 
Fig.9: The Red helper plasmid pKD46 enables efficient homologous recombination with linear DNA 
fragments (adapted from university of Sheffield/Wet Lab). 
 
1.7 Induced gene expression from T7 promoters 
In biotechnology, transcription of cloned genes is often initiated by T7 DNA-
dependent RNAP. This enzyme is recognizing its promoter highly specifically and 
relatively few T7 RNAP molecules are sufficient to drive high-level expression. 
Furthermore, transcription can be reinitiated several times leading to enhanced levels 
of stable RNAs. According to Studier et al. only few hours post induction the protein 
level will accumulate up to 50% or even more of the entire cell protein concentration  
Although highly active, the T7 RNAP is overstressing the translational machinery 
and, thus, the translational efficiency.  
 T7 RNAPs can direct all basic steps necessary for transcription autonomously 
independently from host-encoded transcription factors (Ferrari et al., 2004). 
Structural analysis suggests that transition from initiation to elongation go along with 
conformational rearrangements particularly in the N-terminal domain of the 
polymerase (Theis et al., 2004). Compared to the complex RNAPs, the architecture 
of T7 DNA-dependent RNAPs is rather ordinary with a molecular mass of about 100 
kD. According to structural and functional analysis the T7 RNAP, eukaryotic 
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mitochondrial, chloroplast, other phagelike RNAPs and DNAP of the polymerase I 
family are not homologous (39, 51).  
 The chromosomal integrated lambda DE3 prophage is expressing T7 RNAP 
after induction with IPTG. However, expression of T7 RNAP is controlled by the 
lacUV5 promoter, which is, compared to the wt lac promoter, even active when 
glucose is added to the media (known s catabolite repression). Because of this, 
expression of the transgene in DE3 strains might occur. Normally chromosomally 
integrated λDE3 is inactive in bacterial cells but induction of the SOS cascade may 
lead to its activation leading to cell lysis. Strains expressing T7 polymerase but 
lacking integrated DE3 prophages, are rather insensitive after SOS response 
induction (54). However, it is demonstrated that T7 expressing systems enhance 
gene expression in untreated cells (despite the high specificity for its own promoter), 
influence growth of host cells and its effect on induction is rather low compared with 
gene expression in uninduced cells (Spehr et al., 2000).  
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2 Objectives 
 
The demand for large quantities of highly pure pDNA is arising since gene therapy 
and DNA vaccines make their way into preclinical studies (Carnes et al., 2006). 
Factors such as PCN, structural and segregational stability of plasmids influence the 
efficiency of recombinant protein production in E. coli to a considerable extend (Skulj, 
2008). Expression systems such as the T7 system probably cause exhaustion of the 
protein synthesis machinery but maintenance of the producing population is of 
particular importance in a fermentation process. Excessive overload of the metabolic 
burden of the host can be kept within bounds by regulating PCN. However, upkeep of 
the segregational stability of plasmids is often an intricate problem during the 
fermentation process. Segregational instability usually leads to the emerging and 
enhancement of a plasmid-free population resulting in constrained productivity. All in 
all, retaining low metabolic burden during accumulation of biomass and induction of 
high PCN in the final part of the fermentation process will lead to enhanced plasmid 
yield and plasmid quality. 
 The major object of this work was to evolve a system to regulate the copy 
number of ColE1 plasmids. Two different approaches have been explored: in the first 
approach, upregulation of plasmid concentration by induced expression of tRNAAlaU 
wt and mutated tRNAAlaU (mut) should be carried out. For that reason, tRNAAlaU wt 
and tRNAAlaU mut has been integrated into the E. coli chromosome and its 
expression was controlled by the T7 polymerase. Those strains were transformed 
with 3 different ColE1-plasmids to test if overexpression leads to an enhanced 
plasmid concentration. However, in the majority of IPTG-induced and uninduced cells 
plasmid concentration was marginally increased or even decreased. This was also 
true for uninduced cells due to the leaky T7 promoter. 
 In a second attempt rssB was cloned in a pBSK plasmid to test whether its 
overexpression, induced by the T7 polymerase, lead to enhanced plasmid 
concentration. As in the previous approach, even uninduced cells showed some 
upregulation of plasmid concentration due to the leaky T7 polymerase.
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3 Materials and Methods 
 
3.1 Media 
3.1.1 Media and growth conditions 
All E. coli strains (table 1) used in this work were grown in liquid Luria-Bertani (LB) 
media (table 2) at 37°C and shaken at 190 rpm. Media was supplemented with 
antibiotics or other additives as recommended (table 2). Cells were plated on LB-
agar-plates containing antibiotics (table 3) in case of need. After electroporation, cells 
were transferred into SOC medium (table 4) and incubated with agitation at 37°C 
unless otherwise noted. All media were sterilised by autoclaving for 20 minutes at 
121 °C and 2 bar. 
 
Table 1: Bacterial strains 
Host  Source Genotype Resistance 
JM109 Lab stock recA1 supE44 endA1 hsdR17  
gyrA96 relA1 ∆(lac-proAB) 
- 
MG1655 Lab stock F- lambda- ilvG- rfb-50 rph-1 - 
BL21 (DE3) Novagen F-, ompT, hsdSB(rB-, mB-), dcm, gal,  
λ(DE3) 
- 
HMS174 (DE3) Novagen F- recA1 hsdR(rK12– mK12+) (DE3) RifR 
 
Table 2: LB media: 
Tryptone 10 g/l 
Yeast extract   5 g/l 
NaCl 10 g/l 
 
LB media components were dissolved in 950 ml sterile deionized water, pH value 
was set to 7.0 with 5 molar (M) NaOH and volume was adjusted to 1 liter (l) with 
deionized water. For LB agar, 15 gram (g) agar-agar was added per 1l LB media. 
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The autoclaved media was cooled down to 50°C in a water bath before adding 
antibiotics. 
 
Table 3: Antibiotics and other additives: 
  
Stock solution 
 
End Concentration 
Ampicillin 100 mg/ml 100 µg/ml 
Chloramphenicol 25 mg/ml 25 µg/ml 
IPTG 0.1 M 100 µmol 
Na-Citrate (pH 5.5)  1 M 10 mM 
CaCl2 1 M 5 mM 
Glucose 20% 0.2% 
MgSO4 1 M 10 mM 
 
Antibiotics and other additives were sterilfiltrated (0,22 µm) or autoclaved and stored 
at -20°C. 
 
Table 4: SOC medium 
A bacto tryptone  20 g/l 
 yeast extract    5 g/l 
 NaCl  10 mM 
 KCl    3 mM 
 MgCl2  10 mM 
B glucose*H2O  20 mM 
C MgSO4*7H2O  10 mM 
 
A, B and C were autoclaved separately and mixed subsequently. 
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3.1.2 Shake flask cultures 
The overnight cultures were grown at 37°C with agitation (190 rpm) for 16 hours. 
After overnight incubation, cultures were diluted 1:1000 in 50 ml LB media containing 
the corresponding antibiotics. Gene expression was induced by addition of 100 µmol 
IPTG at an OD600 of 0.5. In parallel, uninduced control cells were considered in all 
experiments.  
 
3.1.3 Bacterial cryostock 
For E. coli conservation at -80°C cryostocks have been prepared. Cells from a single 
colony were incubated in 4 ml LB media supplemented with antibiotics at 37°C 
shaked at 190 rpm. After incubation for 16 hours, 600 µl of cell suspension and 300 
µl glycerine (86%) were transferred into a 1.5 ml sterile Eppendorf tube, immediately 
inverted and frozen at -80 °C. 
 
3.1.4 Bacterial strains and plasmids 
Strains 
All strains and plasmids used in this work are listed in Table 1 and Table 5. 
 
Table 5: Plasmid list 
 
Plasmids  Source Resistance 
 
pBluescript KSII+ 
 
Stratagene 
 
AmpR 
pkD46 kindly provided by Joseph Peters Amp
R, temperature 
sensitive 
pBR322 MBI Fermentas AmpR, TetR 
pUC19 MBI Fermentas AmpR 
pET11a Novagen AmpR 
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3.2 Molecular biological Methods 
3.2.1 Polymerase Chain Reaction (PCR) 
All DNA amplification reactions were carried out in Biometra T3-Thermocycler by 
using the high-fidelity Phusion polymerase (Finnzymes) or Taq polymerase (Biotools 
B&M Labs) according to the manufacturer’s instruction. Lyophilized primers have 
been mixed with sterile water to obtain a stock solution with a final concentration of 1 
ng/µl. A 1:100 dilution of the primer stock solution gave a final concentration of 10 
pmol/µl ready to be used as a primer working solution for PCR reactions. 
Additionally, 2.5 % dimethyl-sulfoxide (DMSO) was applied in the PCR reaction to 
avoid formation of secondary structures in the DNA template and DNA primers. The 
melting temperature (Tm) is the temperature where DNA double helix is separated 
into its single strands and is necessary to determine the stability of a primer-template 
hybrid. A simple formula for calculating Tm is: 
Tm = 4(G + C) + 2(A + T) °C 
3.2.1.1 Colony PCR 
Colony PCR techniques have been employed to screen for positive clones by using 
Taq polymerase. This technique enabled a screening of 8 randomly chosen colonies. 
Individual colonies were picked with a sterile pipette tip and were inoculated in 10 µl 
sterilized water. 3 µl of inoculated cells were pipetted into PCR tubes containing the 
PCR reaction mix. 
 
3.2.1.2 Cloning PCR 
To clone genes, the phusion high-fidelity DNAP is a superior choice since it has 
proofreading function. It has a unique ds-binding domain, fused to a Pyrococcus-like 
proofreading polymerase, which increases the affinity for ds DNA. 
 
3.2.2 Agarose gel electrophoresis and extraction of DNA fragments from 
acrylamid gels 
To separate DNA fragments according to their seize gel electrophoresis (Biorad) was 
performed using a 1 % agarose gel. To obtain 500 ml of liquid agarose solution, 5 g 
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agarose and 10 ml of 50x TAE was mixed and filled up to 500 ml with sterile water. 
For complete dissolution, the solution was heated up in a microwave. After a cool 
down period, 18 µl ethidium bromide was added. Gels were running using 1x TAE 
running buffer after 1:50 dilution of a 50x TAE stock solution (table 6). For sizing ds 
DNA λ DNA EcoRI/HindIII markers are suitable. 6x DNA loading dye (Fermentas) 
contains glycerol that causes samples to sink to the bottom of the wells. Analytical 
gels were run at 130 Volts and preparative gels at 90 Volts. DNA fragments were cut 
out from preparative gels, purified and used for digestion or cloning. For gel 
documentation DNA was visualized under UV-light (Bio-Rad). 
 
Table 6: 50x TAE stock solution 
Tris base 242 g/l 
glacial acid 57.1 ml/l 
0,5 M EDTA (pH 8.0) 100 ml/l 
 
3.2.3 Purification of DNA fragments and PCR products 
PCR products and DNA fragments were purified with commercially available 
products (illustra GFXTM PCR DNA and Gel Band Purification Kit from GE Healthcare 
and Wizard® Plus SV Minipreps DNA Purification System from Promega). The 
purified nucleic acids were eluted in HPLC-clean water. 
  
3.2.4 Plasmid preparation 
pDNA was extracted from 12 ml overnight bacterial culture with the Wizard® Plus SV 
Minipreps DNA Purification System. Finally, pDNA was eluted with 30 µl nuclease 
free water. To gain higher pDNA yield, the Promega Wizard® Plus Midipreps DNA 
Purification System was applied and pDNA was eluted in 600 µl nuclease free water. 
 
3.2.5 Determination of ds-DNA concentration 
DNA-concentration was determined in a spectrophotometer by exposing DNA to 
ultraviolet light at 260 nm. The ratio of A260/A280 reflects the purity of a nucleic acid 
(DNA, RNA) sample and in solution, it averages between 1.8 to 2. 
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3.2.6 Restriction enzyme digestion of DNA 
Restriction digestion with restriction enzymes (NEB) was applied for vector 
linearization, isolation of insert DNA for cloning purposes and control digestions. 
Digestions were conducted with restriction enzymes in reaction buffers that came 
with the restriction enzyme. Some restriction enzymes need Bovine Serum Albumin 
(BSA) to enhance performance and stabilization of the restriction enzymes. All 
restrictions were carried out at 37°C (Eppendorf heating block) for two hours. 
Agarose gel electrophoresis was necessary for analysing or preparation of DNA 
fragments. 
 
3.2.7 Ligation 
To perform successful ligation of insert and vector DNA the T4 DNA Ligase (NEB) 
was used. The standard ligation reaction for DNA was conducted as follows: a 5:1 
molar ratio of insert DNA to vector DNA in a 10 µl set-up is believed to be very 
efficient. The ligation mix containing T4 DNA ligase, T4 ligase buffer, pDNA, insert 
and water, was incubated overnight at 16°C and purified and concentrated with 2-
butanol precipitation as mentioned in section 3.2.9. 
 
3.2.8 Preparation of electrocompetent cells 
A single colony of cells were picked up with a sterile pipette tip and incubated in 20 
ml LB medium containing antibiotics overnight at 37°C with agitation (190 rpm). The 
overnight culture was diluted 1:1000 in a 50 ml fresh LB media and incubated at 
37°C with agitation (190 rpm). The OD600 was measured every thirty minutes. Once 
the OD600 reached 0.5, the culture was transferred in ice-cold Falcon tubes. The cells 
have been harvested by centrifugation at 5000 g for 5 minutes at 4°C. The 
supernatant was decanted and the cell pellet was resuspended in 1 ml ice-cold 
sterile HPLC-water. The suspension was transferred in an ice-cold Eppendorf tube 
and centrifuged at 5000 g for 5 minutes at 4°C (the washing step was repeated 5 
times). Finally, the pellet was resuspended in 50 µl ice-cold sterile HPLC-water. Cells 
were prepared freshly for every electroporation. 
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3.2.9 Concentration and purification of pDNA 
Further concentration and purification steps necessary for electroporation of ligated 
plasmids were carried out with 2-butanol precipitation according to a standard 
protocol: an equal volume of isopropanol (2-butanol) was added to the DNA as well 
as 3 M Na-Acetate and 2-butanol. The sample was incubated at room temperature 
for 10 minutes, and subsequently on ice for further 10 minutes. Centrifugation at full 
speed for 30 minutes at 4°C was carried out. The supernatant was removed and the 
pellet was precipitated with 70% ethanol followed by another centrifugation step for 
10 minutes at 4°C at top speed. The supernatant was removed and the precipitated 
DNA was dried at room temperature for 20 minutes. The purified and concentrated 
DNA was then resuspended in 20 µl sterile water. 
 
3.2.10 Electroporation of purified plasmids 
Electroporation was performed by using Biorad gene pulser at 2.5 kV, 1000 Ω and 25 
µF. For electroporation, self made and ice-cold cuvettes were used by pasting up 
cuvettes with aluminium foil. After electroporation, cells were recovered at 37°C in 
950 µl SOC-medium for 1 hour with agitation (Eppendorf, Thermomixer) and plated 
on LB-Agar plates containing antibiotics for selection. The plates were inversely 
incubated overnight in a 37°C incubator (Heraeus). 
 
3.2.11 Sequencing 
DNA sequencing was performed by AGOWA GmbH (Berlin, Germany). Samples had 
to be diluted with sterile water to the concentrations according to manufacturer’s 
protocol: 
 
 
 
 
 
If sequencing with a custom primer was required, 4 µl of a 5 pmol/µl primer solution 
was added. Universal primers were provided by AGOWA. The sequencing data was 
available in the download area of the AGOWA online order system. 
Template DNA Volume Concentration  
Plasmids 10 µl 100 ng/µl 
PCR products:   
200 – 500 bp 10 µl 10 ng/µl 
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3.3 Genomic engineering 
3.3.1 Construction of the pBR322::TN7<CAT-T7-tRNAAlaU wt> and 
pBR322::TN7<CAT-T7-tRNAAlaU mut> vector 
To construct pBR322::TN7<CAT-T7-tRNAAlaU wt> and pBR322::TN7<CAT-T7-
tRNAAlaU mut> pBR322-MCS was used as the backbone vector (fig.10). To create 
pBR322-MCS, PCR was carried out with the primers KpnI_MCS_for_pBR322 and 
KpnI_MCS_back_pBR322, the Phusion polymerase and pBR322 as a template. After 
PCR, fragments were purified (1874 bp) (see 3.2.3) and subsequently restricted with 
DpnI and KpnI. The KpnI restriction site was located on both primer overhangs 
essential for religation of pBR322-MCS. In the next step, the linear pBR322-MCS 
was religated, transformed in electrocompetent JM109, amplified and isolated. After 
isolation, restriction with SacI and KpnI was done to proof correct ligation because 
only the correct plasmid can be linearised with these enzymes. After isolating the 
correct pBR322-MCS, restriction with SacI and KpnI was carried out to clone 
tRNAAlaU wt and tRNAAlaU mut genes in the plasmid backbone. 
 To gain the inserts, CAT-T7-tRNAAlaU wt and CAT-T7-tRNAAlaU mut were 
excised from the vector pBSK::TN7<CAT-T7-tRNAAlaU wt> and pBSK::TN7<CAT-T7-
tRNAAlaU mut> by using the restriction enzymes SapI and KpnI. After electrophoresis, 
the 1800 bp long fragments have been isolated from the preparative gel and purified. 
Ligation was carried out at 16°C (see 3.2.7) and further concentration and purification 
steps, necessary for electroporation in electrocompetent cells, were conducted with 
2-butanol precipitation (see 3.2.9). Finally, for validation both vectors were cut with 
the restriction enzymes SacI, KpnI as well as SapI and ZraI and have been sent to 
AGOWA for sequencing (see 3.2.11). The correct vectors pBR322::TN7<CAT-T7-
tRNAAlaU wt> and pBR322::TN7<CAT-T7-tRNAAlaU mut> (see fig.10) have been 
electroporated in BL21(DE3) and HMS174(DE3). 
 Construction of the vector pBR322::TN7<CAT-T7-tRNAAlaU mut> could not be 
conducted in this work. 
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Fig.10: The linear cassette including <CAT-T7-tRNAAlaU wt> was inserted into the backbone vector 
pBR322-MCS. 
 
3.3.2 Construction of the pBSK::TN7<CAT-T7-rssB> vector 
To clone rssB in the vector backbone pBSK::TN7<CAT-T7-GFP> (fig. 11), GFP (56 
bp) was eliminated through restriction with BamH1 and NdeI. After restriction, the 
linearised plasmid has been loaded on a preparative gel to cut out the correct band 
(4833 bp) after electrophoresis. rssB was amplified by conducting colony PCR of 
JM109 using Phusion DNAP as well as BamH1 rssB_for and NdeI rssB_back as 
primers. After PCR, rssB fragments (1014 bp) have been loaded on a gel and 
isolated fragments have been purified. Subsequently, rssB has been restricted with 
BamH1 and Nde1, cloned in the linear pBSK::TN7<CAT-T7> vector and ligated at 
16°C (see 3.2.7). After ligation, pBSK::TN7<CAT-T7-rssB> (fig.11) was 
electroporated in electrocompetent JM109 for amplification. To identify correct 
plasmids, restriction analysis was performed by using BamH1 and XbaI as restriction 
enzymes. The proper plasmids have been sequenced by AGOWA and afterwords 
electroporated in HMS174(DE3) and BL21(DE3). 
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Fig.11: GFP from pBSK::TN7<CAT-T7-GFP> was replaced by the gene rssB to create 
pBSK::TN7<CAT-T7-rssB>. 
 
3.3.3 Chromosomal integration via P1 vir phage transduction 
To amplify linear DNA fragments encoding tRNAAlaU and tRNAAlaU mut genes (fig.12) 
pBSK::TN7<CAT-T7-tRNAAlaU wt> and pBSK::TN7<CAT-T7-tRNAAlaU mut> served as 
a template in the PCR reaction using the primers m1320 and T3 blue script. After 
PCR, the DNA fragments have been loaded on a preparative gel. After gel 
electrophoresis bands (1800 bp) were cut out and purified. According to Sauer’s P1 
transduction protocol, MG1655 cells containing pKD46 were cultivated over night in 
LB-amp media and the next day, cells were diluted 1:100 in 50 ml LB-amp containing 
1% arabinose. Cells were grown at 28°C, shaked until the OD600 reached 0.5 and 
made competent (see 3.2.8). For transformation 400 ng of linear DNA fragments 
have been used. After electroporation in MG1655, cells have been inoculated in SOC 
medium for 2 hours at 30°C with agitation and plated on cm-agar plates. Plates have 
been incubated over night at room temperature. Randomly chosen colonies have 
been screened with PCR, using m1320 and T3 blue script primers, for the presence 
of integrated tRNAAlaU wt and tRNAAlaU mut genes and sent to AGOWA for 
sequencing. Recombinant colonies were cured from pKD46 by incubation at 42°C. 
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Fig.12: The linear T7-tRNAAlaU-casette, obtained by PCR, contains the cm resistance gene (CAT) to 
select positive clones. Furthermore, the cassette includes homologous sequences on both ends 
facilitating integration into the hosts BL21(DE3) and HMS174(DE3).  
 
 
The donor strains MG1655::TN7 <CAT-T7-tRNAAlaU wt> and MG1655::TN7<CAT-T7-
tRNAAlaU mut> have been inoculated in an overnight culture (LB media) containing 
cm. The next day the MG1655 strains have been diluted 1:100 in fresh LB medium 
containing 5 mM CaCl2 and 0,2% glucose and incubated with agitation at 37°C for 1 
hour. 50 µl of the P1 page lysate was added to the culture and grown at 37°C until 
the culture has been lysed completely. Several drops of chloroform were added to 
the lysate and vortexted. The debris was centrifuged away (14,000 rpm for 2 
minutes) and the supernatant was transferred to a new tube. A few drops of 
chloroform was added to the lysate and stored at 4°C. 
 The recipient strains BL21(DE3) and HMS174(DE3) were grown overnight in 
12 ml LB medium. The day after, the cells have been harvested by centrifugation 
(6,000 rpm for 2 minutes) and resuspended in the original culture volume in fresh 50 
ml LB media containing cm, 100 mM MgSO4 and 5 mM CaCl2. 100 µl recipient cells 
and 100 µl P1 lysate have been mixed and incubated at 37°C for 30 minutes. 200 µl 
1 M Na-Citrate (pH 5.5) and 1 ml LB media have been added to the lysate and then 
incubated at 37°C for 1 hour to enable expression of cm gene. Subsequently, the 
cells were centrifuged at 6,000 rpm for 3 minutes, resuspended in 100 µl LB media 
containing 100 mM Na-Citrate (pH 5.5) and plated on cm-containing agar plates. The 
agar plates have been incubated at 37°C overnight and, the day after, re-streaked on 
a new plate to isolate cells covering with P1 phage. The re-streaked colonies have 
been screened with PCR (primers m1320, T3 blue script) for the presence of the 
tRNAAlaU wt and tRNAAla mut genes (fig.13) and subsequently sequenced by 
AGOWA. BL21(DE3) and HMS174(DE3) have been transformed with three different 
plasmids (pUC19, pBR322 and pET11a). 
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Fig.13: Chromosomal integration of tRNAAlaU wt/mut in BL21(DE3) via P1 transduction. Site-directed 
point mutations (shown here in green) have been introduced by using mutagenic PCR-primers.  
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4 Results and Discussion 
 
4.1 Regulation of PCN via IPTG-induced expression of tRNAAlaU wt, 
tRNAAlaU mut and rssB 
The object of the following experiments was to increase the PCN in BL21(DE3) and 
HMS174(DE3) by stable chromosomal integration of tRNAAlaU wt and tRNAAlaU mut 
controlled by the IPTG-inducible T7 promoter. Homologous recombination at the 
bacterial transposon Tn7 donor site was conducted by P1 transduction (see 3.3.3). 
To investigate the impact of chromosomally integrated tRNAAlaU wt and mut on the 
replication of ColE1-type plasmids, cells have been electroporated with three 
different plasmids (pET11a, pUC19 and pBR322). A further approach to increase 
PCN of ColE1-derived plasmids was to overexpress rssB, cloned in pBSK. 
In routine shake flask experiments these transformed strains were grown in LB 
medium with and without IPTG induction. For selection cm has been used. pDNA 
concentration was determined at hourly intervals and its concentration was estimated 
by both gel electrophoresis and spectrophotometry. Shake flask experiments and 
plasmid preparations were always conducted in triplicates. 
 
4.1.1 Shake flask experiments and determination of plasmid concentration 
BL21(DE3)::TN7<CAT-T7-tRNAAlaU wt>, BL21(DE3)::TN7<CAT-T7-tRNAAlaU mut>, 
HMS174(DE3)::TN7<CAT-T7-tRNAAlaU wt>, HMS174(DE3)::TN7<CAT-T7-tRNAAlaU 
mut> containing pUC19, pBR322 and pET11a, as well as BL21(DE3) 
pBR322::TN7<CAT-T7-tRNAAlaU wt>, HMS174(DE3) pBR322::TN7<CAT-T7-
tRNAAlaU wt>, BL21(DE3) pBSK::TN7<CAT-T7-tRNAAlaU wt>, BL21(DE3) 
pBSK::TN7<CAT-T7-tRNAAlaU wt>, BL21(DE3) pBSK::TN7<CAT-T7-rssB> and 
HMS174(DE3) pBSK::TN7<CAT-T7-rssB> have been inoculated in an overnight 
culture (12 ml LB-cm media). After 16 hours inoculation, cells have been diluted 
1:1000 in fresh LB-cm media. After cells have reached an OD600 of 0.5, the 
expression of the target gene has been induced with 100 µM IPTG. Uninduced 
control cells have always been considered in this work. In one-hour intervals OD600 
was measured (see table 7), normalized cells have been isolated and centrifuged at 
room temperature. After centrifugation plasmids have been isolated and their 
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concentration has been measured with spectrophotometry. 4 µl of the extracted 
plasmids have been loaded onto an agarose gel to estimate plasmid concentration. 
 
4.1.1.1 OD600 measurement to evaluate bacterial growth 
To measure the optical density of bacterial cultures, overnight cultures were diluted 
1:1000 in 50 ml media containing antibiotics and 100 µM IPTG was added to induce 
overexpression of the candidate gene. In parallel, uninduced control cultures have 
always been included. At one-hour intervals (0h, 1h, 2h, 3h) normalized cells have 
been isolated and OD600 was quantified with a spectrophotometer. Measured OD600 
growth values are listed in table 7. 
 
Table 7: OD600 measurement to evaluate bacterial cell growth 
 
  
- IPTG 
 
 
+ 100 µM IPTG 
 
HOST STRAIN 
 
 
  0h   1h   2h   3h 
  
  0h   1h   2h   3h 
 
BL21(DE3) pBR322-MCS 
 
 
0.518 1.432 2.864 4.034 
 
0.548 1.344 2.526 3.760 
 
HMS174(DE3) pBR322-MCS 
 
 
0.550 1.006 1.614 2.292 
 
0.514 0.940 1.390 1.962 
 
BL21(DE3) pBSK  
 
 
0.542 1.492 3.160 3.876 
 
0.556 1.278 2.936 3.716 
 
HMS174(DE3) pBSK 
 
 
0.528 0.928 1.458 1.870 
 
0.546 0.835 1.424 1.854 
 
BL21(DE3) pBSK::TN7<CAT-T7-
rssB> 
 
 
0.547 1.421 1.983 3.259 
 
0.521 1.298 2.490 3.631 
 
HMS174(DE3) pBSK::TN7<CAT-
T7-rssB> 
 
 
0.502 1.510 2.628 3.692 
 
0.502 1.512 2.600 3.500 
 
BL21(DE3) pBR322::TN7<CAT-T7- 
tRNAAlaU wt> 
 
 
0.512 1.090 2.496 3.516 
 
0.501 0.990 1.000 1.042 
 
 
BL21(DE3)::TN7< CAT-T7-RNAAlaU 
wt> pET11a 
 
0.506 1.394 2.242 3.396 
 
0.589 1.514 2.362 3.378 
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BL21(DE3)::TN7< CAT-T7-RNAAlaU 
mut> pET11a 
 
 
0.584     1.509    2.748     3.760 
 
0.592      1.457     2.718     3.750 
 
BL21(DE3)::TN7<CAT-T7-tRNAAlaU 
wt> pBR322 
 
0.552 1.406 2.414 3.134 
 
0.558 1.288 2.206 2.860 
 
BL21(DE3)::TN7<CAT-T7-tRNAAlaU 
mut> pBR322 
 
0.594 1.422 2.326 3.080 
 
0.576 1.368 2.184 2.826 
 
 
BL21(DE3)::TN7<CAT-T7-tRNAAlaU 
wt> pUC19 
 
 
0.581 1.522 2.211 2.981 
 
0.513 1.499 2.598 3.265 
 
 
BL21(DE3)::TN7<CAT-T7-tRNAAlaU 
mut> pUC19 
 
 
0.532 1.606 2.606 3.872 
 
0.548 1.554 2.512 3.676 
 
 
In BL21(DE3) pBSK::TN7<CAT-T7-tRNAAlaU wt> and BL21(DE3) pBSK ::TN7<CAT-
T7-tRNAAlaU mut> decreasing cell growth rate could be noted (data not shown). 
However, the data obtained from spectrophotometry and gel electrophoresis, where 
plasmid concentration was permanently reduced in the course of shake flask 
experiments, correspond to the decreasing OD600 values. One might conclude that 
overexpression of tRNAAlaU, which may have toxic effects, is the main reason leading 
to reduced or even decreasing growth.  
 However, using the same strain BL21(DE3) but transformed with 
pBR322::T7<CAT-T7-tRNAAlaU wt> showed increasing growth rates in contrast to the 
strains containing pBSK::TN7<CAT-T7-tRNAAlaU wt> and pBSK::TN7<CAT-T7-
tRNAAlaU mut>. In conclusion it is assumed that tRNAAlaU exerted a gene dosage-
dependent effect. Furthermore, HMS174(DE3) pBR322::T7<CAT-T7-tRNAAlaU wt and 
mut> (data not shown), BL21(DE3) pBSK::T7<CAT-T7-rssB>, HMS174(DE3) 
pBSK::T7<CAT-T7-rssB> and the chromosomally inserted wt and mut tRNAAlaU 
genes resulted in enhanced cell growth as well. 
 
4.1.1.2 Determination of plasmid concentration 
According to Summers et al., under most growth conditions natural multicopy ColE1 
plasmids are sustained at steady levels whereas related cloning plasmids are rather 
instable and are frequently lost (10-2-10-5 per cell per generation) because plasmids 
are irregular distributed between daughter cells. Due to this instability, plasmids are 
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lost, PCN is constantly decreasing but multimerization is enhanced. However, natural 
ColE1 plasmids encode cer promoting resolution of multimers to monomers by 
XerCD-mediated recombination. Summers et al. isolated factors affecting 
monomerization and stabilisation of ColE1 when cloned into vectors (37). 
The cloning vectors pBSK and pBR322, used in this work, do not contain the 
stability region cer to maintain plasmids as monomers. In E. coli, Chiang and Bremer 
studied the stability of pBR322-derived plasmids. According to their results, 
multimerization of those plasmids does not impact instability when cells are growing 
in antibiotic-free media. However, pBR322 and its derivatives are low copy-number 
vectors. 
 
4.1.1.2.1 Plasmid concentration of BL21(DE3) pBSK::TN7<CAT-T7-rssB> and 
BL21(DE3) pBSK::TN7<CAT-T7-rssB> 
BL21(DE3) and HMS174(DE3) have been electroporated with the vector 
pBSK::TN7<CAT-T7-rssB>. After isolation of normalized cells, pDNA was isolated 
and 4 µl of the extracted plasmids has been loaded onto an agarose gel to estimate 
plasmid concentration (fig.14). 
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Fig.14: BL21(DE3) and HMS174(DE3) cells have been electroporated with pBSK::TN7‹CAT-T7-rssB› 
whereas rssB was under the control of the T7 promoter. 
 
 According to the results after electrophoresis, rssB was downregulating the 
plasmid concentration in BL21(DE3) leading to segregational plasmid instability and 
loss. However, measurement of cell density during shake flask experiments 
demonstrated stable growth of BL21(DE3) pBSK::TN7‹CAT-T7-rssB› (see table 7). 
Concluding from the control BL21(DE3) pBSK, the plasmid concentration was 
constantly reduced after IPTG induction. After all, results indicated that rssB itself 
was not causing segregational instability but the plasmid pBSK itself in the host 
BL21(DE3). 
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 In contrast to BL21(DE3), plasmid concentration in HMS174(DE3) 
pBSK::TN7‹CAT-T7-rssB› was enhanced despite of decreasing plasmid 
concentration in the control cells HMS174(DE3) harbouring pBSK. That implies that 
rssB expressed in HMS174(DE3) is a factor contributing to enhanced plasmid 
concentration. Furthermore, in both cases rssB was expressed with and without 
induction due to the T7 promoter. 
Results from Sarkar et al. results revealed when rssB was overexpressed in a 
K-12 strain, PCN increased four-fold. In contrast to the procedure implemented in this 
work, they transformed a pcnB::kan K-12 strain with the ColE1 pET19b-based T7-
expression vector containing the rssB gene. So, rssB was overexpressed in a pcn- 
background by IPTG-induction but in our experimental set-up both strains are pcn+. 
Concluding from that, rssB could not perform its suppressor function in a pcn+ 
background and four-fold upregulation of plasmid concentration was not possible in 
that extent. 
 
4.1.1.2.2 Plasmid concentration of BL21(DE3) pBR322::TN7<CAT-T7-tRNAAlaU wt 
Genetically engineered BL21(DE3) cells have been electroporated with the vector 
pBR322::TN7<CAT-T7-tRNAAlaU wt>. After isolation of normalized cells, pDNA was 
isolated. To determine plasmid concentration, spectrophotometry was applied and 4 
µl of the extracted plasmids have been loaded onto an agarose gel (fig.15). 
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Fig.15: BL21(DE3) cells have been electroporated with pBR322::TN7<CAT-T7-tRNAAlaU wt> whereas 
tRNAAlaU was under the control of the T7 promoter. 
 
Both data gained from spectrophotometry and gel electrophoresis demonstrated 
clearly increasing plasmid concentration after IPTG induction. Concluding from that 
tRNAAla wt might contribute to increasing plasmid concentration. Results gained from 
BL21(DE3) pBR322::TN7<CAT-T7-tRNAAlaU mut> could not be demonstrated in this 
work. 
 Viacheslavov and Mosevitskiĭ could show that the plasmid pBR322 in E. coli B exist 
in two forms after its isolation as it could be demonstrated in this work (see fig.15): 
monomers as well as multimers. It is a fact that plasmid multimerization contribute to 
decreased plasmid concentration still tRNAAla wt could play its role as an enhancer of 
plasmid concentration. 
 
4.1.1.2.3 Plasmid concentration of BL21(DE3)::TN7<CAT-T7-tRNAAlaU wt/mut> 
pBR322, pUC19 and pET11a 
BL21(DE3)::TN7<CAT-T7-tRNAAlaU wt> and BL21::TN7<CAT-T7-tRNAAlaU mut> have 
been electroporated with the plasmids pBR322, pUC19 and pET11a. After isolation 
of normalized cells, pDNA was isolated, 4 µl of the extracted plasmids have been 
loaded onto an agarose gel to estimate plasmid concentration (fig.16). 
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Fig.16: BL21(DE3)::TN7<CAT-T7-tRNAAlaU wt> and BL21::TN7<CAT-T7-tRNAAlaU mut> have been 
electroporated with the plasmids pBR322, pUC19 and pET11a. 
 
Electrocompetent BL21(DE3)::TN7<CAT-T7-tRNAAlaU wt> and BL21::TN7<CAT-T7-
tRNAAlaU mut> cells have been electroporated with three different ColE1-type 
plasmids (pBR322, pET11a and pUC19). The impact of induced overexpression of 
tRNAAlaU wt and mut on plasmid concentration has been tested in shake flask 
experiments. Comparing the OD600 values of induced, uninduced and control cell 
lines showed clearly no major difference (see table 7) while overexpression of 
tRNAAlaU wt and mut had an enhancing effect on plasmid concentration according to 
the digital photo taken after gel electrophoresis (see fig.16). 
 Furthermore, experimentally gained data have demonstrated definitely that 
overexpression of tRNAAlaU wt as well as tRNAAlaU mut influenced plasmid 
concentration in the same extent in all 6 strains. Contradictory to our assumption 
tRNAAlaU molecules with mutations in G2 and C71 should result in enhanced plasmid 
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concentration compared to tRNAAlaU wt. In vivo and in vitro experiments confirmed 
that AlaRS is recognizing both the discriminator base A73 of tRNAAlaU and the first 4 
bp of the acceptor stem (Beuning et al., 2002) to initiate the aminoacylation process. 
Recognition of tRNAAlaU helix by AlaRS is clearly reduced after the base transversion 
G2:C71 and the same is true for its aminoacylation status (6). Concluding from that 
both point mutations of tRNAAlaU mut should contribute to increasing unloaded 
tRNAAlaU molecules. 
 Wang et al. have chosen tRNAAlaU(UGC) as a model tRNA to enhance PCN by 
its overexpression in amino-acid starved RelA mutants. It is believed that the majority 
of tRNAAlaU(UGC) molecules remain uncharged when media lacking amino-acids 
have been used. Furthermore, they assumed that the interaction between 3’-ACCA 
of the uncharged tRNA and the UGGU sequences within the RNAI loops are 
necessary to produce a catalytic structure that somehow cleave RNAI only in the 
presence of Mg2+ (8). The chosen strains in this work were all RelA+ in contrast to the 
RelA mutants applied in this paper. Furthermore, cells used in this work did not grow in 
amino-acid starved media but to imitate the amino-acid starved situation, the tRNAAlaU 
encoding gene was mutated by a base transversion at G2:C71 at the second position in 
the tRNAAlaU helix (6). According to the publication the base transversion turned out to 
have a tremendous effect on recognition by AlaRS leading to a significant loss of 
aminoacylation, Thus, mutated tRNAAlaU molecules, used in this work, should be 
uncharged under these conditions. 
 Despite the high specificity of the T7 promoter for its own phage-like promoter, 
expression of the transgene in uninduced cells has been observed as well. 
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5 Conclusion and Outlook 
Most individuals are carriers of defective, usually recessive, genes and some of them 
have or will come down with genetic diseases or disorders. By now, 2800 
monofactorial genetic diseases are known to affect people’s medical condition. 
Nevertheless, diagnostic tests have to be available to allow treatment of genetic 
diseases.  
 About $200 million per year will support the Human Genome Program in the 
U.S. to localize and determine all human genes, thus gaining information which is 
beneficial for gene therapy progress and prospect. Until now, gene defects causing 
Duchenne muscular dystrophy, cystic fibrosis, and retinoblastoma have been 
determined, and further relevant information about various genetic defects will be 
received in the future. Furthermore, several organizations such as the genetic 
disease foundation (GDF) have been founded to assist in diagnosis and treatment of 
genetic disorders. People expect that improvements in the field of molecular 
medicine will contribute to identification and treatment of various diseases within the 
next years to improve people’s medical condition. Many clinical trials have been 
successful, whereas other failed. 
  Nearly all gene therapy trials include treatment of cancer and many of these 
progress to an advanced stage, involving Phase III. Although serious progress has 
been made on gene therapy in less than two decades, there is still necessity to 
evolve enhanced and safer methods to deliver genes into cells. Using naked DNA in 
gene therapy approaches has turned out as a convenient method but to be applied in 
individuals, pDNA has to be highly pure and homogenous.  
 Basically, various factors could raise PCN involved in reducing intracellular 
concentration of RNAI, increasing RNAII levels or involved in preventing RNAI-RNAII 
complexes (Sarkar et al., 2002).  
 In this work the main goal was to elaborate a system that regulates plasmid 
replication of ColE1-type plasmids in E. coli. However, both overexpression of the wt 
and mut tRNAAlaU molecules as well as rssB resulted in increased plasmid 
concentration.
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7 Appendix 
 
 
Primer sequences: 
 
 
TN7 extern1 5'-ACCGGCGCAGGGAAGG-3' 
TN7 extern2 5'-TGGCGCTAATTGATGCCG-3' 
KpnI_MCS_for_pBR322 5'-GGCGGGGTACCCGGGGATCCT 
CTAGAGATAAGCTGTCAAA-3' 
Kpn_MCS_back_for_pBR322 5'-ATGATGGGTACCGAGCTCGAAT 
TCGCACCATTATGTTCCGGATC-3' 
m1320 5‘-TGTAAAACGACGGCCAGTG-3’ 
T3 blue script 5’-CGCGAGCGATTGTACTGAAG-3’ 
catbeginfor 5’-TACCTTTTAAGCTTCCTTAGCT-3’ 
T7prom 5‘-CAACGGTGGTATATCCAGTG-3’ 
pJensnestedfor 5’-TAATACGACTCACTATAGGG-3’ 
T7term 5’-GCTAGTTATTGCTCAGCGG-3' 
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aaRS aminoacyl-transfer RNA synthetases 
AAV Adeno-associated viruses 
ADA Adenosine Deaminase 
AIDS  Acquired Immune Deficiency Syndrome 
amp ampicillin 
AmpR ampicillin resistance 
APC antigen-processing cell 
ATP Adenosine triphosphate 
Bp base pairs 
BSA Bovine Serum Albumin  
Cm chloramphenicol 
CmR chloramphenicol resistance 
CTL cytotoxic T lymphocyte 
ctRNAs countertranscribed RNAs 
DMSO dimethyl-sulfoxide 
DNA  desoxyribonucleic acid 
DNAP DNA polymerase 
dNTP deoxy nucleotide triphosphates 
DPCs MEA-dynamic PolyConjugates 
E. coli Escherichia coli 
EMEA European Agency for the Evaluation of 
Medicinal Products 
FDA Food and Drug Administration 
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GFP Green Fluorescent Protein 
GOI gene of interest  
G gram 
H hours 
HIV  Human immunodeficiency virus 
HSV Herpex simplex virus 
IgG Immunoglobulin G 
ITR inverted terminal repeats 
IPTG isopropyl β-D-thiogalactopyranoside 
Kan kanamycin 
KanR kanamycin resistance 
L liter 
LB media Luria-Bertani media 
M molar  
MEAs masked endosomolytic agents 
MHC major histocompatibility complex 
mRNA messenger RNA 
mut mutated  
NaCl sodium chloride 
OD600 optical density at a wavelength of 600 nm 
ORI origin of replication 
PAC P1 artificial chromosome 
PCN plasmid copy number 
PCR polymerase chain reaction 
pDNA plasmid DNA 
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PPi inorganic pyrophosphate 
ppGpp guanosine tetraphosphate 
RNA ribonucleic acid 
Rom RNA One Modulator  
Rop Repressor of primer  
rRNA ribosomal RNA 
SCID severe combined immunodeficiency 
Ss single-stranded 
SV Synthetic vehicles 
SV40 Simian-Virus 40 
Tet tetracycline 
TetR Tetracycline resistance  
Tm melting temperature 
tRNA transfer ribonucleic acid 
WHO World Health Organization 
Wt wild type 
XSID X-linked severe combined 
immunodeficiency 
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Volksschule 09/1980 bis 06/1984 Wien 
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Handelsschule 09/1988 bis 06/1991 Wien 
Handelsakademie 09/1992 bis 02/1994 Wien 
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(Zweiter Bildungsweg) 09/1994 bis 09/2001 Wien 
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Universität Wien, Studium  
der Biologie (Studienzweig 
Genetik/Mikrobiologie)  10/2003 bis 12/2010 
